Zhejiang Huahai Pharmaceutical Co Ltd (600521.SS)
21 Sep 2018
Mon, Sep 17 2018
(This version of the September 14th story changes final paragraph to show representative did not immediately respond to a request for comment)
SHANGHAI/LONDON A toxin inadvertently produced in the manufacture of a widely prescribed medicine but not spotted for years raises questions about regulators' ability to detect risks in a sprawling global drug supply chain increasingly reliant on factories in China.
SHANGHAI China's health regulator has ordered local medical institutions to stop using a heart drug from Zhejiang Huahai Pharmaceutical Co Ltd, in a directive that comes just days after another case of a tainted medical product.
* Chinese drugmaker stocks trade lower (Recasts; adds analyst comment)
SHANGHAI, July 30 China's health regulator has called on all medical institutions to cooperate with authorities and not use the valsartan blood and heart drug that is said to pose cancer risks.